The Phase II trial ran for eight weeks, but the study data analysis has taken much longer. The treatment could generate significant revenues for the company is commercialised since it could treat all types of irritable bowel syndrome (IBS). LBP Blautix is the only drug candidate globally that has demonstrated effectiveness against both IBS-C and IBS-D.
Investors will be hoping the company’s management will provide timelines on when phase III trials will begin and chart a path towards regulatory approval.
Since March, the biotech company’s shares have been falling, but today’s announcement pushed the shares above 101p resistance level, and I’ll be monitoring the stock from now on to see if the level will hold.Ĥd Pharma will hold a webcast tomorrow to discuss the results in detail. Their bowel habits also improved significantly as compared to the group that was taking the placebo. The company noted statistically significant results on bowel habits among US participants compared to British and Irish patients who had a high response to the placebo drug.ĤD Pharma noted that patients receiving LBP Blautix noticed a progressive decrease in abdominal pains during the trial.
0 kommentar(er)
